Phase 2 N=7 Pharmacotoxicology of Trichloroethylene Metabolites
Healthy
Primary: Plasma DCA (Microgram/ml) After 5 Days of Therapeutic Level Chloral Hydrate on Arm 2A. — 1.64 micrograms/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=365 Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Carcinoma · Adenocarcinoma · Renal Cell
Primary: Progression-free Survival (PFS) of Participants Who Received RAD001 Plus Bevacizumab Versus Participants Who Received IFN Plus Bevacizumab — 9.3; 10.0 Months
Phase 2 N=41 Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
Recurrent Thyroid Cancer · Stage IV Follicular Thyroid Cancer · Stage IV Papillary Thyroid Cancer
Primary: Proportion of Patients Who Have Remained on Treatment and Progression-free at Least One Year After Start of 17-AAG (Tanespimycin) — 5.9; 12.5 percentage of participants
Phase 2 N=163 Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine
Meningococcal Disease
Primary: Persistence of Geometric Mean Antibody Titers in Children (Who Previously Received 4 Doses of Men B Vaccine), at 40 Months of Age. — 3.24; 5.34; 4.25; 5.11 Titers
Phase 2 N=697 Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age
Streptococcal Infections
Primary: The Percentages of Non-pregnant Subjects With Antibody Concentrations Above a Defined Threshold at One Month After the Second Vaccination. — 91; 37; 91; 32 percentage of…
Phase 2 N=100 Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
Exudative Age-Related Macular Degeneration · Focal Vitreomacular Adhesion
Primary: Proportion of Subjects With Focal Vitreomacular Adhesion (VMA) Release by Day 28 — 24.3; 12.0 percentage of subjects — p=0.262
Phase 2 N=120 Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis
Multiple Sclerosis · Cognitive Ability, General
Primary: Primary Outcome is Performance on the Interference Condition of the Stroop, the Long Delay Free Recall Portion of the California Verbal Learning Test II, the 2 Second…
Phase 2 N=74 Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation
Acute Graft Versus Host Disease
Primary: Percentage of Participants With Evidence of Acute Graft Versus Host Disease (aGVHD), Post Transplant — 43; 89 percentage of participants
Phase 2 N=58 Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease
Alzheimer's Disease
Primary: Change in the Area Under the Curve of Plasma Aβ1-40 in the 2 or 4 Weeks After the Last Treatment Infusion From the Trough Level Prior to the Last Treatment Infusion…
Phase 2 N=21 VEGF Trap in Treating Patients With Metastatic Breast Cancer
Metastatic Breast Cancer · Recurrent Breast Cancer · Stage IV Breast Cancer
Primary: Proportion of Patients With Confirmed Tumor Response — 1; 20 Participants
Phase 2 N=111 A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis
Moderate to Severe Chronic Plaque Psoriasis
Primary: Percentage of Participants With at Least 50 Percent (%) Reduction in Psoriasis Area Severity Index (PASI) Score at Week 12 or Early Termination — 20.0; 20.0; 17.9; 20.0…
Phase 2 N=36 Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung Disease
Cystic Fibrosis
Primary: Change in Sputum Elastase Activity — -57 micrograms/mL
Phase 2 N=284 Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure
Chronic Renal Insufficiency · Diabete Mellitus · Congestive Heart Failure
Primary: Comparison of Overall Image Quality Between Ioforminol and Iopamidol-enhanced Images as Determined by an Independent Reader. — 65; 71; 57; 59 Number of subjects
Phase 2 N=9 G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers
Healthy
Primary: Number of Participants With Successful Apheresis Collection Following Combination of AMD3100 and G-CSF. — 8; 1 participants
Phase 2 N=16 Effect of Aromatase Inhibitors on Breast Magnetic Resonance Imaging (MRI)
Breast Cancer
Primary: Number of Women With Reduced Breast Parenchymal Enhancement — 7 Number of participants